

May 25, 2018

Listing Department
BOMBAY STOCK EXCHANGE LIMITED
P J Towers, Dalal Street, Fort,
Mumbai-400 001

Code: 532321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: CADILAHC

Re: **Audited Financial Results for the quarter / year ended on March 31, 2018**

Dear Sir,

Please find attached herewith the audited financial results for the quarter / year ended on March 31, 2018, reviewed by the Audit Committee and taken on record by the Board of Directors today i.e. May 25, 2018 pursuant to Regulation No. 33[2][a] of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015.

Please receive the same in order.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**


UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above



Statement of Results for the Quarter and Year Ended 31/03/2018

Rupees in Million					Rupees in Million				
Sr. No.	Particulars	CONSOLIDATED				COMPANY			
		3 Months ended 31/03/2018 (Audited)	Preceding 3 months ended 31/12/2017 (Unaudited)	3 months ended 31/03/2017 in the previous year (Audited)	Year to date figure for the current period ended 31/03/2018 (Audited)	3 Months ended 31/03/2018 (Audited)	Preceding 3 months ended 31/12/2017 (Unaudited)	3 months ended 31/03/2017 in the previous year (Audited)	Year to date figure for the current period ended 31/03/2018 (Audited)
1	Revenue								
a	Revenue from operations	31,527	31,798	24,527	116,306	13,918	15,046	7,666	55,887
i	Sales	975	677	606	3,056	633	692	619	2,339
ii	Other operating income	32,502	32,475	25,133	119,564	14,551	15,738	8,285	54,226
iii	Total revenue from operations	287	410	731	1,132	305	580	4,045	2,079
b	Other income	32,789	32,885	25,864	120,496	14,856	16,318	12,331	60,305
c	Total revenue								
2	Expenses								
a	Cost of materials consumed	7,595	6,560	5,389	25,233	4,083	4,333	2,767	15,640
b	Purchases of stock-in-trade	4,531	4,946	4,393	19,141	947	831	266	3,186
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,293)	(323)	(552)	(3,154)	(755)	(618)	(305)	(1,869)
d	Excise Duty on Sales	0	0	467	315	0	0	83	127
e	Employee benefits expense	4,915	4,655	4,054	18,545	2,331	2,023	1,640	8,260
f	Finance costs	1,440	1,334	98	5,388	253	27	(38)	639
g	Depreciation and amortisation expense	8,050	8,204	6,737	30,809	4,058	3,225	545	2,931
h	Other expenses	25,392	25,645	21,727	97,188	11,704	12,451	8,183	48,333
i	Total expenses	7,387	7,240	4,137	23,308	3,152	3,867	4,148	14,972
3	Profit before exceptional items, tax and share of profit/ (loss) of joint ventures (1-2)	0	0	0	0	0	0	0	0
4	Exceptional items	7,387	7,240	4,137	23,308	3,152	3,867	4,148	14,972
5	Profit before tax and share of profit/ (loss) of joint ventures (3-4)	7,387	7,240	4,137	23,308	3,152	3,867	4,148	14,972
6	Tax expenses	2,053	1,800	1,203	6,436	706	824	270	3,183
a	Current tax	(611)	(14)	(1,184)	(792)	14	(21)	(836)	881
b	Deferred tax	1,442	1,786	19	5,644	720	803	(566)	4,064
c	Total tax expenses	5,955	5,454	4,118	17,664	2,432	3,064	4,714	10,908
7	Profit before share of profit/ (loss) of joint ventures (5-6)	195	105	(179)	628	0	0	0	0
8	Share of profit/ (loss) of joint ventures (net of tax)	6,150	5,559	3,939	18,292	2,432	3,064	4,714	10,908
9	Net Profit before Non-Controlling Interests (7+8)	83	101	70	346	0	0	0	0
10	Non-Controlling Interests	6,067	5,458	3,869	17,946	2,432	3,064	4,714	10,908
11	Net Profit after tax, Non-Controlling Interests and share of profit/ (loss) of joint ventures from continuing operations (8-10)	(159)	(25)	(14)	(188)	0	0	0	0
a	Profit/(loss) before tax from discontinued operations	0	0	0	0	0	0	0	0
b	Tax expense of discontinued operations	(159)	(25)	(14)	(188)	0	0	0	0
c	Profit/(loss) after tax from discontinued operations	5,908	5,433	3,855	17,758	2,432	3,064	4,714	10,908
13	Other Comprehensive Income (OCI)								
a	Items that will not be reclassified to profit or loss:								
i	Re-measurement gains/ (losses) on post-employment defined benefit plans	136	(95)	(122)	(151)	87	(70)	(13)	(122)
ii	Net Gain/ (Loss) on Fair Value through OCI Equity Securities	(37)	24	163	459	(36)	153	159	458
iii	Income tax effect on above items	60	83	56	345	(19)	15	(8)	26
iv	Total	(360)	149	256	(132)	32	98	138	362
b	Items that will be reclassified to profit or loss:								
i	Exchange differences on translation of foreign operations	(18)	0	0	(18)	0	0	0	0
ii	Exchange differences on translation of discontinued foreign operations reclassified to Statement of Profit and Loss	0	0	0	0	0	0	0	0
iii	Income tax effect on above items	(378)	149	256	(150)	0	0	0	0
iv	Total	2	(2)	(4)	0	0	0	0	0
c	Share of OCI of joint ventures (net of tax)	(316)	230	308	195	32	98	138	362
d	Other Comprehensive Income, net of tax	5,675	5,764	4,233	18,299	2,464	3,162	4,852	11,270
15	Total Comprehensive Income (9+12+14)	5,992	5,663	4,163	17,953	2,464	3,162	4,852	11,270
16	Total Comprehensive Income attributable to:								
a	Owners of the Company	83	101	70	346	0	0	0	0
b	Non-Controlling Interests	1,024	1,024	1,024	86,421	1,024	1,024	1,024	1,024
17	Reserves excluding Retention Reserve as per balance sheet of previous accounting year (i.e. Other Equity)								
a	Basic (Rs.)	5.93	5.33	3.78	17.53	2.38	2.99	4.60	10.66
b	Diluted (Rs.)	5.93	5.33	3.78	17.53	2.38	2.99	4.60	10.66
18	Earnings per share for discontinued operations (not annualised)								
a	Basic (Rs.)	(0.16)	(0.02)	(0.01)	(0.18)	-	-	-	-
b	Diluted (Rs.)	(0.16)	(0.02)	(0.01)	(0.18)	-	-	-	-
19	Earnings per share for continuing & discontinued operations (not annualised)								
a	Basic (Rs.)	5.77	5.31	3.77	17.35	2.38	2.99	4.60	10.66
b	Diluted (Rs.)	5.77	5.31	3.77	17.35	2.38	2.99	4.60	10.66

Notes :

- [1] The above financial results for the quarter and year ended March 31, 2018 were reviewed by the Audit Committee on May 24, 2018 and thereafter approved and taken on record by the Board of Directors at their meeting held on May 25, 2018.
- [2] The Board of Directors have recommended a dividend of Rs. 3.50/- (@ 350%) per equity share on 204,748,520 equity shares of Re. 1/- each for the financial year ended on March 31, 2018. The recommended dividend is subject to the approval of the shareholders at the ensuing Annual General Meeting.
- [3] Pursuant to the Share and Loan Purchase Agreement dated April 17, 2018 ["Closing Date"] amongst the Company, Zydus International Private Limited, Ireland ["ZIRL"], Brenner Pharma GmbH ["Brenner"] and Alivira Animal Health Limited, Ireland ["Alivira"], the Company has sold its 100% equity holding and ZIRL has sold and transferred its outstanding loan together with accrued interest in Brenner to Alivira with effect from April 01, 2018 ["Effective Date"].

In accordance with Ind AS 105 "Non-Current Assets held for Sale and Discontinued Operations" and as required under Schedule III of the Companies Act, 2013, the operations of Brenner are classified as Discontinued Operations and disclosed separately for the current quarter and year ended March 31, 2018. Operations of Brenner for the preceding quarter ended December 31, 2017, corresponding quarter ended March 31, 2017 and previous year ended March 31, 2017 have also been reclassified and disclosed separately under the head "Profit / (Loss) from the Discontinued Operations".

Net assets of discontinued operations have been measured at their fair value, being the value at which equity shares of Brenner have been transferred to Alivira. Total assets and total liabilities of discontinued operations as at March 31, 2018 have been separately disclosed in the statement of assets and liabilities as at March 31, 2018.

Summarised financial information of discontinued operations is disclosed below:

Sr. No.	Particulars	Rupees in Million				
		3 Months ended 31/03/2018 (Audited)	Preceding 3 months ended 31/12/2017 (Unaudited)	Corresponding 3 months ended 31/03/2017 in the previous year (Audited)	Year to date figures for the current period ended 31/03/2018 (Audited)	Previous year ended 31/03/2017 (Audited)
a	Total Revenue	132	122	116	496	532
b	Total expenses	158	147	130	551	559
c	Profit/ (loss) before tax	(26)	(25)	(14)	(55)	(27)
d	Tax Expense	0	0	0	0	0
e	Profit/ (loss) after tax	(26)	(25)	(14)	(55)	(27)
f	Loss recognized on measurement of net assets to fair value	(133)	0	0	(133)	0
g	Total Profit/ (loss) after tax from discontinued operations	(159)	(25)	(14)	(188)	(27)

Includes impairment of Goodwill of Rs. 92 Million and cumulative gain on exchange differences arising on translation of discontinued operations Rs. 18 Million.

- [4] Pursuant to the agreement between Zydus Healthcare Limited ["Zydus"], a wholly owned subsidiary of the Company and Acme Pharmaceuticals Private Limited ["Acme"] dated March 29, 2018 ["Effective Date"], Zydus has acquired 100% of equity shareholding of Acme. The consolidated financial statements for the quarter and year ended March 31, 2018 include the operations of Acme for the period from the Effective Date to March 31, 2018 after considering provisional Purchase Price Allocation (PPA) as at Effective Date.
- [5] The Company has incorporated Violo Pharmaceuticals Limited ["Violo"] as a wholly owned subsidiary of the Company on May 10, 2018. Violo has incorporated its step down wholly owned subsidiary, Violo Pharmaceuticals Inc. in the United States of America as on May 11, 2018.
- [6] Pursuant to the terms of the Joint Venture Agreement (JVA) between the Company and Bayer [South East Asia] Pte. Limited ["Bayer"] dated, January 28, 2011, the Company has sold 12,500,001 equity shares of Bayer Zydus Pharma Private Limited to Bayer on April 27, 2018.
- [7] The Government of India introduced the Goods and Service Tax (GST) with effect from July 1, 2017 which replaces excise duty and various other indirect taxes. As per Ind AS 18 "Revenue", Revenue from operations for the quarter ended December 31, 2017 is reported net of GST. Revenue from operations for the periods upto June 30, 2017 are reported inclusive of excise duty, which is now subsumed in GST. Revenue from operations for the year ended March 31, 2018 includes excise duty upto June 30, 2017.
- [8] Exceptional items for the previous year ended March 31, 2017 represents provision for various expenses related to the closure of business operations in Japan of Rs. 3 Million.
- [9] The figures of the quarter ended March 31, 2018 are balancing figures between audited figures in respect of the full financial year and restated year to date figures upto the third quarter of the current financial year.
- [10] Figures of previous reporting periods have been regrouped/ reclassified to conform to current period's classification.
- [11] The Company has one segment of activity viz., "Pharmaceuticals".





A Ahmedabad, May 25, 2018

CONSOLIDATED		COMPANY	
Rupees in Million		Rupees in Million	
As at current year end 31/03/2018	As at previous year end 31/03/2017	As at current year end 31/03/2018	As at previous year end 31/03/2017
Particulars			
A ASSETS			
1 Non-current assets			
a Property, plant and equipment	38,157	25,454	22,050
b Capital work-in-progress	15,772	6,592	6,784
c Goodwill	13,853	18	18
d Other intangible assets	12,816	1,330	1,452
e Investments in joint ventures	3,605	0	0
f Financial assets			
i Investments	1,104	36,181	39,237
ii Loans	0	13,013	14,271
iii Other Financial Assets	1,529	1,212	2,242
g Deferred Tax Assets (Net)	9,246	0	0
h Other non-current assets	2,034	1,722	2,492
i Assets for Current tax (Net)	740	541	534
Sub-total - Non-current assets	98,356	86,063	89,080
2 Current assets			
a Inventories	23,853	13,207	9,329
b Financial assets			
i Investments	2,748	0	0
ii Trade receivables	32,063	12,551	9,290
iii Cash and cash equivalents	5,367	1,786	168
iv Bank balance other than cash and cash equivalents	7,782	52	0
v Loans	0	176	371
vi Other current financial assets	3,448	3,317	1
c Other current assets	6,744	4,423	2,235
Sub-total - Current assets	82,005	35,514	21,394
Assets classified as held for sale	292	60	0
TOTAL - ASSETS	180,653	121,637	110,474
B EQUITY AND LIABILITIES			
1 Equity			
a Equity share capital	1,024	1,024	1,024
b Other equity	86,421	76,431	65,159
c Equity attributable to equity holders of the Company	87,445	77,455	66,183
d Non-controlling Interest	1,910	0	0
Sub-total - Equity	89,355	77,455	66,183
2 Non-current liabilities			
a Financial liabilities			
i Borrowings	25,551	13,511	12,394
ii Other financial liabilities	524	87	82
b Provisions	1,559	741	621
c Deferred tax liabilities (Net)	2,821	1,936	1,055
d Other Non-Current Liabilities	13	0	0
Sub-total - Non-current liabilities	30,468	16,275	14,152
3 Current liabilities			
a Financial liabilities			
i Borrowings	25,575	13,009	15,456
ii Trade payables	18,884	9,921	9,961
iii Other financial liabilities	13,352	4,110	4,009
b Other current liabilities	1,387	347	415
c Provisions	1,002	283	273
d Current tax liabilities (Net)	520	237	25
Sub-total - Current liabilities	60,720	27,907	30,139
Liabilities directly associated with assets classified as held for sale	110	0	0
TOTAL - EQUITY AND LIABILITIES	180,653	121,637	110,474

By Order of the Board,
For Cadila Healthcare Limited,

Dr. Shantil P. Patel
Managing Director